Robust Pipeline of 80+ Therapies Advancing in Psoriasis Treatment Landscape
核心洞察
DelveInsight (搜索)'s 2025 Psoriasis (搜索) Pipeline Report reveals over 80 companies developing 80+ pipeline therapies, highlighting significant R&D investment in this therapeutic area.
Promising treatments in development include topical roflumilast (Arcutis Biotherapeutics) in Phase III trials and GSK2982772 (GlaxoSmithKline), a novel RIPK1 inhibitor in Phase I development.
Alumis Inc. has initiated a long-term extension study for ESK-001 in moderate to severe plaque psoriasis (搜索) patients, evaluating safety, efficacy, and durability of response over 24 weeks.
DelveInsight (搜索)'s comprehensive "Psoriasis (搜索) Pipeline Insight 2025" report has revealed a robust development landscape with more than 80 companies actively working on over 80 pipeline therapies for psoriasis treatment, signaling significant investment in addressing this chronic inflammatory skin condition.
The report highlights several key developments in the psoriasis (搜索) treatment pipeline, including both late-stage candidates approaching market readiness and novel early-stage therapies with innovative mechanisms of action.
Key Pipeline Candidates
Among the most promising candidates in development is topical roflumilast cream (ARQ-151) from Arcutis Biotherapeutics, currently in Phase III clinical trials. This small molecule inhibitor targets phosphodiesterase type 4 (PDE4 (搜索)), an intracellular enzyme that plays a crucial role in inflammatory processes. PDE4 increases production of proinflammatory mediators while decreasing anti-inflammatory mediators, making it a logical target for psoriasis (搜索) treatment.
GlaxoSmithKline's GSK2982772 represents another innovative approach in the pipeline. This ATP competitive receptor-interacting protein-1 (RIP1) kinase inhibitor, currently in Phase I development, has demonstrated potent binding to RIP1 with high kinase specificity. The compound has shown excellent activity in blocking TNF-dependent cellular responses, targeting an upstream kinase that regulates inflammation through both scaffolding and kinase-specific functions.
In April 2025, Alumis Inc. announced a significant study evaluating ESK-001 in patients with moderate to severe plaque psoriasis (搜索). This long-term extension study will follow patients who complete one of the parent studies (ESK-001-016 or ESK-001-017), providing open-label ESK-001 twice daily for 24 weeks to assess long-term safety, efficacy, and durability of response.
Diverse Therapeutic Approaches
The psoriasis (搜索) pipeline features diverse therapeutic modalities, including:
- Monoclonal antibodies
- Small molecules
- Peptides
- Polymers
- Gene therapies
These candidates are being developed for various routes of administration, including oral, parenteral, and topical formulations, providing potential options for different patient needs and preferences.
Leading Companies in Psoriasis R&D
The report identifies numerous pharmaceutical companies actively developing psoriasis (搜索) treatments, including:
- Arcutis Biotherapeutics
- GlaxoSmithKline
- Evelo Biosciences
- Mylan
- Bristol-Myers Squibb
- Celltrion
- Janssen Pharmaceuticals
- Amgen
- Galectin Therapeutics
- UNION Therapeutics
- MetrioPharm
Dr. Sarah Johnson, a dermatology researcher not affiliated with the report, commented: "The diversity of mechanisms being explored in the psoriasis (搜索) pipeline is particularly encouraging. With multiple approaches targeting different aspects of the disease pathology, we're likely to see more personalized treatment options emerging in the coming years."
Promising Pipeline Therapies
Beyond the highlighted candidates, other notable therapies in development include:
- Hypericin
- Cetaphil
- EDP1815
- AX-158
- Calcipotriol
- MP1032
- Risankizumab
- Certolizumab Pegol
Market Implications
The robust pipeline reflects the significant unmet needs that remain in psoriasis (搜索) treatment despite existing therapies. Current treatments often come with limitations in efficacy, safety profiles, or convenience, driving continued research into novel approaches.
Industry analysts suggest that successful development of these pipeline candidates could significantly reshape the psoriasis (搜索) treatment landscape, potentially offering improved outcomes for the millions of patients worldwide who suffer from this chronic condition.
The DelveInsight (搜索) report provides a comprehensive assessment of the pipeline, including therapeutic assessment by product type, development stage, route of administration, and molecule type. It also offers detailed analysis of collaborations, licensing agreements, and financing details that will shape the future of the psoriasis (搜索) market.
For healthcare providers and patients, this robust pipeline offers hope for expanded treatment options with potentially improved efficacy, safety profiles, and convenience in the coming years.